In a clinical cohort of ovarian cancer, we show that the patients whose tumours have high levels of expression of MRE11 and low levels of expression of BRCA2 have poor rates of PFS, implying that targeting MRE11 could be clinically relevant. Here, MRE11 is linked to neoplasm.